MorphoSys Shares Gap Up to 5.52
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
Shares of MorphoSys AG gapped up before the market opened on Friday . The stock had previously closed at 5.52, but opened at 5.74. MorphoSys shares last traded at 5.71, with a volume of 25,128 shares changing hands. MorphoSys Trading Up 2.5 percent The firm has a market cap of 775.01
Read at thelincolnianonline.com
 |
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
MorphoSys is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| GOSS | Gossamer Bio | 3.53 | ||||
| RLYB | Rallybio Corp | 3.23 | ||||
| IMCR | Immunocore Holdings | 1.62 | ||||
| PCVX | Vaxcyte | 1.26 | ||||
| REPL | Replimune | 0.57 | ||||
| ELVN | Enliven Therapeutics | 0.09 | ||||
| CGEM | Cullinan Oncology | 0.16 | ||||
| GLUE | Monte Rosa | 0.57 | ||||
| PMVP | Pmv Pharmaceuticals | 0.67 | ||||
| GBIO | Generation Bio | 0.93 | ||||
| EWTX | Edgewise Therapeutics | 1.33 | ||||
| NVCT | Nuvectis Pharma | 1.53 | ||||
| MLYS | Mineralys Therapeutics, | 1.68 | ||||
| VTYX | Ventyx Biosciences | 1.79 | ||||
| KRON | Kronos Bio | 2.06 | ||||
| ACLX | Arcellx | 2.12 | ||||
| IMRX | Immuneering Corp | 3.43 | ||||
| IPSC | Century Therapeutics | 3.85 | ||||
| CCCC | C4 Therapeutics | 3.96 | ||||
| LYRA | Lyra Therapeutics | 4.55 | ||||
| MRSN | Mersana Therapeutics | 5.33 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |